PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Am Chem Soc. Author manuscript; available in PMC 2010 October 14.
Published in final edited form as:
PMCID: PMC2760011
NIHMSID: NIHMS146292

Post-Synthetic Modifications of Iron-Carboxylate Nanoscale Metal-Organic Frameworks for Imaging and Drug Delivery

Abstract

An external file that holds a picture, illustration, etc.
Object name is nihms146292u1.jpg

Fe(III)-carboxylate nanoscale metal-organic frameworks (NMOFs) with the MIL-101 structure were synthesized using a solvothermal technique with microwave heating. The ~200 nm particles were characterized using a variety of methods, including SEM, PXRD, nitrogen adsorption measurements, TGA, and EDX. By replacing a percentage of the bridging ligand (terephthalic acid) with 2-amino terephthalic acid, amine groups were incorporated into the framework to provide sites for covalent attachment of biologically relevant cargoes while still maintaining the MIL-101 structure. In proof-of-concept experiments, an optical contrast agent (a BODIPY dye) and an ethoxysuccinato-cisplatin anticancer prodrug were successfully incorporated into the Fe(III)-carboxylate NMOFs via post-synthetic modifications of the as-synthesized particles. These cargoes are released upon the degradation of the NMOF frameworks, and the rate of cargo release was controlled by coating the NMOF particles with a silica shell. Potential utility of the new NMOF-based nano-delivery vehicles for optical imaging and anticancer therapy were demonstrated in vitro using HT-29 human colon adenocarcinoma cells.

Metal-organic frameworks (MOFs) are a class of hybrid materials with infinite tunability that results from the limitless choice of metals and organic bridging ligands.1 MOFs can also be designed to exhibit unprecedentedly high porosity.2 Among the tens of thousands of known MOFs, the MIL family built from trivalent metal centers and dicarboxylate bridging ligands pioneered by Férey and co-workers has particularly attracted a great deal of attention due to their enhanced stability, enormous porosity, and very large pores.3 For example, MIL-101 (Cr) with the formula Cr3F(H2O)2O(BDC)3·nH2O (where n is ~25) has a Langmuir surface area of up to 5900 m2/g and contains two types of mesoporous cages with internal free diameters of ~29 Å and 34 Å.4 The combination of these features makes the MIL family a unique candidate for storage and controlled release of biologically important molecules. Indeed, Férey and co-workers have elegantly demonstrated the loading of organic drug molecules in the large pores of the bulk phases of MILs via physical absorption.5 They have shown that MIL-101 (Cr) can adsorb 138 wt% ibuprofen, and MIL-53 can adsorb 22 wt% ibuprofen.5 The release of ibuprofen from the MILs was evaluated using simulated body fluid at 37 °C. It was found that the MIL-101 (Cr) release ibuprofen slowly in several stages, reaching completion after 6 days.5a The MIL-53 materials showed an even slower release, reaching completion after 21 days.5b

In order for MOFs to be useful as efficient delivery vehicles for drugs and imaging contrast agents, the material composition must be biocompatible and the particle sizes must be carefully controlled to be uniform and below several hundred nanometers.6 We have recently demonstrated the potential application of nanoscale metal-organic frameworks (NMOFs) in magnetic resonance imaging and anticancer drug delivery.7 The imaging and drug components in the previous systems were directly incorporated into the NMOFs either as metal-connecting points or as bridging ligands during the NMOF sysnthesis.7 Herein we report a new strategy of delivering an imaging contrast agent and an anticancer drug by post-synthetic modifications of a highly porous NMOF. We demonstrated for the first time the synthesis of an iron-carboxylate NMOF of the MIL-101 structure and the loading of an organic fluorophore and an anticancer drug via covalent modifications of the as-synthesized nanoparticles.8 The potential utility of such a novel nano-delivery system in optical imaging and anticancer therapy were also demonstrated in vitro.

Fe(III) NMOF particles with the framework formula of Fe33-O)Cl(H2O)2(BDC)3 (1) were synthesized in modest yields (typically ~20%) by heating a solution of equimolar FeCl3 and terephthalic acid (BDC) in DMF at 150 °C with microwave heating. The particles were isolated by centrifuging and washed with DMF and ethanol to remove any unreacted starting materials. Scanning electron microscopy (SEM) images show that the particles of 1 have an unusual octahedron morphology and an average diameter of ~200 nm (Figure 1a). Powder X-ray diffraction (PXRD) studies indicated that particles of 1 are highly crystalline and of the same structure as the MIL-101 (Cr) (Figure 2).4 To our knowledge, the Fe(III) analog of the MIL-101 (either in the bulk phase or the nanoparticle form) has not been previously reported. Nitrogen adsorption studies showed that particles of 1 are highly porous with a Langmuir surface area ranging from 3700 to 4535 m2/g, a value that is slightly lower than that reported for the bulk MIL-101 (Cr). The slightly lower porosity of 1 as compared to the bulk phase of MIL-101 (Cr) is presumably due to structural defects present in the nano-sized MIL-101 (Fe).

Figure 1
(a) SEM image of Fe33-O)Cl(H2O)2(BDC)3 nanoparticles (1). (b) SEM image of nanoparticles of 1a with 17.4 mol% NH2-BDC. (c) SEM of nanoparticles of 1a loaded with the BODIPY dye (1b). (d) SEM image of nanoparticles of 1a loaded with c,c,t-[PtCl ...
Figure 2
PXRD patterns of MIL-101 (Cr) simulated form the CIF file, MIL-101 (Fe) nanoparticles (1), amino-containing nanoparticles (1a), silica-coated particles (1a@silica), and BODIPY-loaded particles (1b).

In order to allow for post-synthetic modifications of the MIL-101 (Fe) nanoparticles, we attempted to synthesize amino-functionalized particles of 1 (denoted as 1a) by incorporating 2-aminoterephthalic acid (NH2-BDC). Interestingly, as shown by PXRD studies, although the particles of 1a with low NH2-BDC incorporation (up to 17.5 mol% of NH2-BDC in the feed) exhibited the same MIL-101 structure as 1 (Figure 2), the particles with higher NH2-BDC incorporation (greater than 20 mol% of NH2-BDC in the feed) adopted the MIL-88B structure (denoted as 2, see supporting info).9 The amount of NH2-BDC incorporated into 1a was quantified by NMR after digesting the particles with Na4EDTA and methylating the carboxylate groups of BDC and NH2-BDC. The ratio of NH2-BDC incorporation was slightly higher than the ratio in the feed in most cases except the sample with 17.5 mol% NH2-BDC in the feed that had 17.4 mol% NH2-BDC incorporation. The sizes and morphologies of the 1a particles are similar to those of 1 regardless of the NH2-BDC percentage (Figure 1b).10 The 1a particles with 17.4 mol% NH2-BDC were used for all the subsequent studies in this work.

The presence of amino groups on the particles of 1a allows for covalent attachment of biologically relevant cargoes through post-synthetic modifications (Scheme 1). Based on our previous work, we expect NMOFs 1 and 1a to be biodegradable and to provide an interesting nano-delivery vehicle for imaging contrast agents and anticancer drugs by slow release of the cargoes via the NMOF degradation. We first loaded a potential optical imaging contrast agent by treating 1a particles with 1,3,5,7-tetramethyl-4,4-difluoro-8-bromomethyl-4-bora-3a,4a-diaza-s-indacene (Br-BODIPY) in THF at r.t. for 2 days. The BODIPY-loaded particles (1b) were isolated by centrifuging, and the unreacted dye was removed by washing with THF. The BODIPY loading was determined to be 5.6–11.6 wt% based on the absorbance of the BDC-NH-BODIPY dye (at 498 nm) after digesting the 1b particles with Na4EDTA. This corresponds to an NH2-BDC to BDC-NH-BODIPY conversion efficiency of 20.9 to 40.3%. Thermogravimetric analysis (TGA) showed an increased weight loss that is consistent with the BODIPY grafting. SEM images show that the sizes and morphologies of the particles 1a remain essentially unchanged after BODIPY loading (Figure 1c). PXRD studies indicated the particles of 1b maintain the MIL-101 structure (Figure 2). BODIPY-grafted 1b is non-emissive due to luminescence quenching by the d-d transitions of the Fe(III) centers.

We also loaded a prodrug of cisplatin into 1a by post-synthetic modification. The ethoxysuccinato-cisplatin (ESCP) prodrug, c,c,t-[PtCl2(NH3)2(OEt)(O2CCH2CH2CO2H)], was first activated by 1,1-carbonydiimidazole and then reacted with a dispersion of 1a in DMF at room temperature. The ESCP-loaded particles 1c were isolated by centrifuging and washed with DMF and ethanol. SEM imaging showed no change in the particle size or morphology after ESCP loading (Figure 1d) whereas PXRD studies showed that the ESCP-loaded particles (1c) retained the MIL-101 structure. The ICP-MS results showed that the Pt/Fe weight ratio for 1c with 16 mol% NH2-BDC was 0.208. A Pt/Fe weight ratio of 0.559 would be expected if all the amino groups had been functionalized with the ESCP. 37.3% of all the available NH2-BDC groups in 1c were thus functionalized with ESCP. For a sample of 1c with 17.4 mol% NH2-BDC, a Pt/Fe weight ratio of 0.244 was obtained, which represents a conversion efficiency of 40.2% of NH2-BDC to BDC-NH-ESCP. Amino-functionalized MIL-101 (Fe) nanoparticles thus provide an efficient platform for delivering the ESCP prodrug with an overall payload of 12.8 wt%. Particles 1c with 17.4 mol% NH2-BDC were used for subsequent experiments.

The covalent grafting of BODIPY and ESCP allowed us to determine the stability of MIL-101 (Fe) nanoparticles in biologically relevant media. As the BODIPY dye is released from the 1b particles, the solution exhibits fluorescence signal characteristic of the BDC-NH-BODIPY species. The release of the BODIPY dye from 1b was determined by measuring the fluorescence spectra of the aliquots at different time points. As shown in Figure 3, the BDC-NH-BODIPY dye is readily released from the 1b particles with a t1/2 of ~2.5 h in 8 mM PBS buffer at 37 °C. Since the BODIPY dye is covalently attached to the NH2-BDC via the robust amine linkage, the release of BODIPY must be due to the degradation of the 1b particles. Consistently with this, the recovered particles lost the diffraction peaks due to the MIL-101 structure, suggesting the formation of the amorphous iron phosphate (Scheme 1). We verified the degradation of MIL-101 (Fe) nanoparticles in PBS buffer by examining the release of BDC-NH-ESCP from the 1c particles.11 ICP-MS studies indicated that the BDC-NH-ESCP was steadily released from 1c with a t1/2 of ~1.2 h in PBS buffer at 37 °C (Figure 3).

Figure 3
Release profile of the BDC-NH-BODIPY dye from the particles of 1b in PBS buffer at 37 °C (black) as determined by fluorescence spectroscopy. Release profiles of the BDC-NH-ESCP from the particles of 1c (red) and 1c@silica (blue) in PBS buffer ...

Because of the instability of the nano-sized MIL-101 (Fe) particles in PBS buffer, we attempted to slow down the cargo release by coating the particles with a thin silica layer. Numerous attempts using a previously established procedure based on base-catalyzed hydrolysis of tetraethoxysilane led to the decomposition of the particles of 1.12 The nano-sized MIL-101 (Fe) particles readily decompose under basic conditions to presumably form amorphous iron hydroxide (oxide) phases. An alternative procedure using Na2SiO3 as the silica source led to successful coating of MIL-101 (Fe) nanoparticles with a uniform layer of silica. SEM imaging showed no discernible change of the morphology upon silica coating (Figure 1e) but energy dispersive X-ray (EDX) analysis showed the presence of silicon (with a Si/Fe molar ratio of 1.4) in the particles of 1@silica. Consistent with this, TGA analysis indicated a decreased percent weigh loss (by ~26%) in the 200–400 °C temperature range. More importantly, the BODIPY-loaded particles of 1b and ESCP-loaded particles of 1c were also successfully coated with silica shells using this procedure to lead to novel core-shell nanostructures denoted 1b@silica and 1c@silica, respectively. EDX and TGA studies indicated the coating of 1b and 1c particles with silica shells, while SEM and PXRD showed no change in the morphology or structure after silica coating (Figure 1f and supporting info). Interestingly, the release of BDC-NH-ESCP from 1c@silica is significantly retarded with a t1/2 of ~14 h in PBS buffer at 37 °C, presumably due to the slow diffusion of the relatively large BDC-NH-ESCP through the silica shell (Figure 3). Consistent with this, the t1/2 for the BDC-NH-BODIPY release from 1b@silica was increased to ~16 h in PBS buffer at 37 °C. The silica-coated 1b and 1c particles thus have adequate stabilities for biological applications.

We have evaluated the in vitro effectiveness of 1b@silica as an optical contrast agent. Laser scanning confocal microscopy studies on HT-29 human colon adenocarcinoma cells showed fluorescent labeling in a dose dependent manner (Figure 4). The BODIPY fluorescence was present in cells incubated with 1b@silica, but absent in cells incubated without nanoparticle. We believe that the BDC-NH-BODIPY dye is slowly released from the 1b@silica particles after their internalization by the cells. Control studies with the BDC-NH-BODIPY dye showed no fluorescence (supplementary information), presumably due to its inability to cross the cell membrane. The nano-sized MIL-101 (Fe) particles thus provide an efficient platform for delivering the optical contrast agent in vitro.

Figure 4
Overlayed DIC and confocal fluorescence images of the DRAQ5 channel (blue, nuclear stain) and the BDC-NH-BODIPY channel (green) of HT-29 cells incubated with no particles (a), 0.19 mg/mL of 1b@silica particles (equivalent to 17 μM BODIPY) (b), ...

Nanoparticles of 1c were also evaluated to determine their anticancer efficacy on the HT-29 cell line. Treatment of HT-29 cells with nanoparticles of 1c@silica showed appreciable cytotoxicity (IC50=29 μM); however, it was slightly less cytotoxic than cisplatin under the same conditions (IC50=20 μM). The released ESCP from 1c@silica would presumably become active inside cells via reduction to cisplatin by endogenous biomolecules such as glutathione.13 To increase the cytotoxicity of 1c@silica, we functionalized the silica shell with silyl derived c(RGDfK). c(RGDfK) is a cyclic peptide known to target the αvβ3 integrin, which is overexpressed in many angiogenic tumors.14 Cytotoxicity tests of RGD-targeted 1c@silica gave a similar cytotoxicity (IC50=21 μM) as cisplatin (IC50=20 μM).

In summary, we have synthesized an iron-carboxylate NMOF of the MIL-101 structure. We have demonstrated a new strategy of delivering high payloads of imaging contrast agents and anticancer drugs by post-synthetic modifications of highly porous NMOFs. The generality of this approach should allow the design of a wide range of nanomaterials for imaging and therapeutic applications.

Supplementary Material

1_si_001

Acknowledgments

We thank NIH (U54-CA119343) and NSF (DMR-0605923) for financial support and Dr. Liqing Ma for experimental help. K.M.L.T.-P. thanks the University of North Carolina for a dissertation fellowship.

Footnotes

Supporting Information Available: Experimental procedures, characterization data, and in vitro assays. This material is available free of charge via the internet at http://pubs.acs.org.

References

1. (a) Eddaoudi M, Kim J, Rosi N, Vodak D, Wachter J, O’Keeffe M, Yaghi OM. Science. 2002;295:469. [PubMed] (b) Kitagawa S, Kitaura R, Noro S. Angew Chem Int Ed. 2004;43:2334–2375. [PubMed] (c) Evans OR, Lin W. Acc Chem Res. 2002;35:511. [PubMed]
2. Li H, Eddaoudi M, O’Keeffe M, Yaghi OM. Nature. 1999;402:276–279.
3. Ferey G, Mellot-Draznieks C, Serre C, Millange F. Acc Chem Res. 2005;38:217–225. [PubMed]
4. Férey G, Mellot-Draznieks C, Serre C, Millange F, Dutour J, Surblé S, Margiolaki I. Science. 2005;309:2040–2042. [PubMed]
5. (a) Horcajada P, Serre C, Vallet-Regí M, Sebban M, Taulelle F, Férey G. Angew Chem Int Ed. 2006;45:5974–5978. [PubMed] (b) Horcajada P, Serre C, Maurin G, Ramsahye NA, Balas F, Vallet-Regí M, Sebban M, Taulelle F, Férey G. J Am Chem Soc. 2008;130:6774–6780. [PubMed]
6. (a) Lin W, Rieter WJ, Taylor KML. Angew Chem Int Ed. 2009;48:650–658. [PubMed] (b) Spokoyny AM, Kim D, Sumrein A, Mirkin CA. Chem Soc Rev. 2009;38:1218–1227. [PubMed]
7. (a) Rieter WJ, Taylor KML, An H, Lin W, Lin W. J Am Chem Soc. 2006;128:9024–9025. [PubMed] (b) Rieter WJ, Pott KM, Taylor KML, Lin W. J Am Chem Soc. 2008;130:11584–11585. [PubMed] (c) Taylor KML, Rieter WJ, Lin W. J Am Chem Soc. 2008;130:14358–14359. [PubMed]
8. For leading references in post-synthetic modifications of MOFs, see: (a) Kiang YH, Gardner GB, Lee S, Xu Z, Lobkovsky EB. J Am Chem Soc. 1999;121:8204–8215. (b) Seo JS, Whang D, Lee H, Jun SI, Oh J, Jeon YJ, Kim K. Nature. 2000;404:982–986. [PubMed] (c) Wu CD, Hu A, Zhang L, Lin W. J Am Chem Soc. 2005;127:8940–8941. [PubMed] (d) Wang Z, Cohen SM. J Am Chem Soc. 2007;129:12368–12369. [PubMed] (e) Mulfort KL, Farha OK, Stern CL, Sarjeant AA, Hupp JT. J Am Chem Soc. 2009;131:3866–3868. [PubMed] (f) Wang Z, Cohen SM. Chem Soc Rev. 2009;38:1315–1329. [PubMed]
9. During this research, a report appeared on the synthesis of the bulk Fe MIL-101 phase with purely NH2-BDC bridging ligands. However, our conditions only produced the Fe MIL-88B phase when 100 mol% NH2-BDC was used. Bauer S, Serre C, Devic T, Horcajada P, Marrot J, Férey G, Stock N. Inorg Chem. 2008;47:7568–7576. [PubMed]
10. Some reactions resulted in the formation of small amounts of micron sized particles, which could be easily separated from the desired nanoparticles by centrifuging at low speeds (3000 rpm).
11. Upon decomposition of the nano-sized MIL-101 (Fe) in phosphate buffer, some of the Fe3+ ions form an insoluble material, likely some forms of iron phosphates, which are not released from the dialysis bag. Therefore ICP-MS analysis for Fe released from the dialysis bag does not give true stability results.
12. (a) Rieter WJ, Taylor KML, Lin W. J Am Chem Soc. 2007;129:9852–9853. [PubMed] (b) Lu Y, Yin Y, Mayers BT, Xia Y. Nano Lett. 2002;2:183.
13. (a) Carr JL, Tingle MD, McKeage MJ. Cancer Chemother Pharmacol. 2002;50:9. [PubMed] (b) Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ. J Am Chem Soc. 2007;129:8438. [PubMed]
14. Lee JW, Juliano RL. Mol Biol Cell. 2000;11:1973. [PMC free article] [PubMed]